Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that cyproterone acetate treatment in late-pubertal trans-girls was safe, well-tolerated, and induced mild feminizing changes, with more pronounced effects when combined with estrogens.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

This retrospective study found that cyproterone acetate, both alone and with estrogens, was safe, well tolerated, and induced modest feminizing effects in late-pubertal transgender female adolescents.

This study found that high-dose cyproterone acetate was effective for treating hirsutism, but 33% of patients felt their condition worsened on low-dose maintenance therapy, despite no significant change in objective measures of hair growth.

This study reported that treatment with cyproterone acetate alone and then with incremental estrogen doses induced mild feminizing effects in late-pubertal trans-girls, with further feminization observed after adding estrogen.

This study found that combined treatment with anastrozole and cyproterone acetate improved the adult height prognosis in testotoxicosis, as observed in two brothers, with good tolerance reported.

Cyproterone and finasteride reduced hypersexuality but caused serious side effects.

This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.

In this study, cyproterone acetate at 2 mg daily was found to be as effective as higher doses in reducing hair growth for hirsute women over 12 months.

This case study reports a 66-year-old woman developing shortness of breath while taking 50 mg/day of cyproterone acetate for androgenetic alopecia, a complication not previously documented in women with this condition.

This study observed some differences in clinical outcomes when comparing CPA with spironolactone, flutamide, and finasteride, but no differences with other therapies, possibly due to small study size and non-standardized assessments; adverse effects could not be fully compared across treatments.

This article discusses the mechanisms of hirsutism and acne in women, highlighting cyproterone acetate with ethinyloestradiol as an effective anti-androgen therapy in the UK, but it reports no new clinical findings.

This study found a strong dose-related increase in the risk of intracranial meningiomas associated with high doses of cyproterone acetate, with some reduction in risk after stopping the treatment.

This review outlines chlormadinone acetate's contraceptive and non-contraceptive applications but reports no new clinical findings, emphasizing its potential in treating dysmenorrhea and androgen-related conditions.

This study describes the molecular conformation and intermolecular interactions in the crystalline structure of the compound C24H31BrO4.

In this study, low doses of cyproterone acetate with ethinylestradiol were as effective as low-dose flutamide in reducing acne severity in hyperandrogenic women, while finasteride was less effective.

This study found that treatment with cyproterone acetate and ethinylestradiol in hirsute women reduced testosterone and androstenedione levels, decreased hair growth, and increased cortisol levels without changing catecholamine excretion.

This review discusses hormonal influences and treatment considerations in female acne, particularly highlighting the role of androgens in persistent or resistant cases, and reports no new clinical findings.

In this study, most surveyed physicians were aware of the meningioma risk linked to cyproterone acetate monotherapy, but many did not recall receiving updated safety communications.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

This study reported that 44% of hirsute women undergoing cyproterone acetate treatment experienced impaired sexual enjoyment, highlighting the need to inform patients about potential side effects.

This study found that cyproterone acetate, given with ethinyl oestradiol, significantly reduced hirsutism in women after 12 months, although improvements reversed once cyproterone acetate was stopped.

Cyproterone helps women with hair loss caused by genetics. More research is needed to confirm the best dose.

This review highlights that Cyproterone acetate combined with ethinylestradiol is highly effective for treating severe acne and hirsutism in women with hyperandrogenism, and it also provides benefits for cycle control and mood improvement, according to the analysis of 78 studies.

A new compound was made that might help treat diseases related to male hormones.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

This study observed that most hirsute patients on combined cyproterone acetate and 'Diane' therapy experienced a reduction in hair growth, with hair becoming softer, thinner, and lighter in color over 12 months.

This study found that females exposed to high cumulative doses of cyproterone acetate had a 6–20 fold increased risk of developing meningiomas compared to those on lower doses.

This study found that both cyproterone acetate alone and combined with ethinyl oestradiol reduced androgen levels and slightly increased SHBG binding in women with hirsutism, but showed no difference in hair regrowth rate between the treatments.

This article reviews the medical history and symptoms related to hyperandrogenism in patients, but reports no new clinical findings.